Tech Support Analyst

Kaiser tops U.S. News' best Medicare Advantage list. Kaiser Permanente leads the 2027 list of best Medicare Advantage companies from U.S. News & World Report, with an overall rating of 4.4 out of 5. UnitedHealthcare, Humana, Aetna and Devoted Health round out the top tier, each rated 3.8, according to the ratings published Oct. 14. The ratings matter because they arrive at the start of Medicare's annual open enrollment, which runs Oct. 15 through Dec. 7, when beneficiaries compare plans. They also offer a second, independently weighted view of insurer quality alongside CMS's Star Ratings released earlier in October. The best Medicare Advantage companies for 2027. U.S. News named five companies as best overall for Medicare Advantage: * Kaiser Permanente: 4.4 * UnitedHealthcare: 3.8 * Humana: 3.8 * Aetna: 3.8 * Devoted Health: 3.8 Three of the five, Aetna, Devoted Health and UnitedHealth Group, were also named best Medicare Advantage companies in the 2026 edition, according to U.S. News' 2026 announcement. Kaiser Permanente and Humana are new to the top list for 2027. U.S. News also recognized top companies in three consumer-focused categories: highest satisfaction, screening and prevention, and care continuity. How U.S. News rated insurers. U.S. News rates Medicare Advantage contracts on a five-point scale, assigning its own weights to more than 30 quality measures published by CMS. Those weights do not necessarily match the ones CMS uses for Star Ratings. U.S. News then calculates an enrollment-adjusted average rating for each company. To be named among the best, a company needed an overall rating of at least 3.8 after rounding and had to serve at least 1,000 beneficiaries as of December 2025 in each of 10 or more states or territories where it still offers coverage for 2027. The ratings covered both standalone Medicare Advantage contracts and those that include Part D drug coverage. Part D leaders unchanged. For standalone prescription drug coverage, the same two companies earned best overall recognition in both 2026 and 2027. Humana scored 3.8 and Centene scored 3.5 for 2027, according to U.S. News. To qualify as a top Part D company, an insurer needed at least 1,000 Part D beneficiaries in each of at least 10 jurisdictions where it still offers 2027 coverage, and an enrollment-weighted average rating of at least 3.5 after rounding. How the ratings compare with CMS stars. The U.S. News results broadly track this year's CMS Star Ratings, which showed Humana rebounding sharply, with 95 percent of its Medicare Advantage members in plans rated 4 stars or higher, up from about 20 percent. Aetna and UnitedHealthcare saw their share of members in 4-star-or-better plans decline, though both still met U.S. News' threshold. Because U.S. News applies its own weighting and requires a presence in at least 10 states, its list highlights larger multistate carriers. Strong regional plans may appear instead in U.S. News' state-by-state rankings. Those state-level ratings recognize a wider field. In the 2026 edition, fewer than one-third of Medicare Advantage insurers nationwide earned a best insurance company designation in at least one state, according to Geisinger Health Plan, which was named a best company in Pennsylvania that year. Regional and provider-owned plans such as Geisinger's often compete closely with national carriers in their home markets even when they fall short of the 10-state requirement for the national list, giving beneficiaries more top-rated options to compare locally. What it means for beneficiaries and plans. For beneficiaries, the ratings are one input among several. Plan networks, drug formularies, premiums and out-of-pocket costs vary widely by county, and a highly rated company may not offer the best plan in a given area. For insurers, appearing among the best Medicare Advantage companies can be a marketing advantage during open enrollment. Unlike CMS Star Ratings, the U.S. News ratings do not affect federal quality bonus payments, but they shape how consumers and brokers view plan quality as enrollment decisions are made.

UnitedHealth targets No Surprises Act arbitration wins as Congress weighs ending IDR. UnitedHealth says No Surprises Act arbitration awards are its biggest cost pressure. What practices that use IDR should document now. UnitedHealth Group told Wall Street on Oct. 13 that No Surprises Act arbitration awards are the biggest cost problem in its employer business and accused a small number of clinician groups of abusing the dispute process. Practices that depend on those wins should expect the country's largest payer to fight harder to shrink them. Physician groups have heard the argument before. "If the payers are hiding behind the more egregious cases, I don't think they are really addressing the main issue, which is that providers still prevail the vast majority of the time," Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association (MGMA), told Physicians Practice in. Gilberg acknowledged a few outrageous cases and some profit-driven ownership arrangements but called them "the exception to the rule." On the company's third-quarter earnings call, executives said arbitration awards can approach nearly 6 percent of total medical spend in some regions, with some awards running 10 to 11 times what Medicare would pay, according to. They said UnitedHealth will keep working with policymakers and regulators to make sure the law works as Congress intended. The warning came in a strong quarter. UnitedHealth reported $4.1 billion in profit, up from $2.3 billion a year earlier, and a medical loss ratio of 88.4 percent, down from 89.9 percent,. But spending in employer-sponsored plans ran high for a second straight quarter, and executives pointed to arbitration payouts, pricier specialty drugs and providers billing more aggressively,. They put commercial cost trend above 11 percent and pointed to rising cost intensity from clinicians. Why the timing matters. UnitedHealth is making its case while Congress debates whether arbitration should exist at all. Rep. Frank Pallone Jr. (D-N.J.), ranking member of the House Energy and Commerce Committee, introduced the Lower Premiums, Faster Payments Act on Oct. 8. According to, it would end open negotiation and IDR for services furnished on or after Jan. 1, 2028, make the qualifying payment amount (QPA) the out-of-network rate, require payment within 30 days and bar judicial review of how the QPA is calculated. The same analysis notes the bill's near-term prospects look limited with Pallone in the minority. Still, the largest payer publicly tying arbitration to employer premiums hands lawmakers and regulators a ready talking point. For now, the numbers favor providers. They won 88 percent of resolved disputes in the first quarter of 2024 and 83 percent in the second, and the median winning provider offer ran 383 percent to 447 percent of the QPA, according to. Five organizations accounted for 63 percent of resolved cases, the kind of concentration UnitedHealth is pointing to. Volume keeps climbing. Parties started more than 2.1 million disputes from Jan. 1 through July 31, 2026, according to. Of the 671,465 disputes closed in June and July, 98,398, or nearly 15 percent, were found ineligible. What it means for practices. For an independent group that relies on arbitration, the cost intensity complaint is the part to watch. When a payer names clinician billing as a driver of employer costs, practices can expect closer scrutiny of coding levels, more downcoding and more records requests on out-of-network claims. The best defense is a clean file on every dispute. list what certified IDR entities look for: the complete remittance or denial notice with its codes, a full explanation of benefits, the claim number and the QPA. Practices should also keep the emails or portal records showing they started the 30-business-day open negotiation period, because they must produce them if the payer says negotiation never happened. CMS flags incorrect batching as one of the most common mistakes. The raises the bar further. Open negotiation notices now go through the federal portal, each party pays a $15 administrative fee per dispute, batched disputes are capped at 50 line items and parties get five business days to answer an IDR entity's request for more information. Winning is only half the job. Gilberg said in June that providers prevail more than 80 percent of the time "only to receive no payment," and called for "more accountability so that when a provider prevails in the IDR process, they actually get paid in a timely manner." The courts have not filled that gap. On Sept. 17, the 2nd U.S. Circuit Court of Appeals ruled that a provider could not sue Cigna to collect more than $3 million in unpaid awards and pointed it to federal agencies and states for enforcement,. UnitedHealth did not say what it will ask regulators for. Pallone's bill would not take effect before 2028 even if it passed, so arbitration remains the path for today's disputes, and practices that document every step will be in the strongest position however the policy fight ends.

UnitedHealth Q3 2026 earnings beat masks a growth stall. UnitedHealth Group's (NYSE: UNH) UnitedHealth Q3 2026 earnings landed well clear of where the market had braced for, and the stock rewarded it: shares touched $395.33 on 13 October, up 3.76% on the day and 5.23% over the preceding month, according to UnitedHealth's own results statement. The insurer also raised its full-year profit guidance for the second quarter running - but the underlying numbers suggest this is a story about clawing back margin that was lost in 2025, not one about the business getting bigger. The headline figures: revenue of $112.7 billion, GAAP diluted earnings per share of $4.56, and adjusted earnings per share of $4.69, with earnings from operations of $6.6 billion, all drawn from the company's third-quarter filing with the SEC. Chief executive Stephen Hemsley attributed the quarter to "the discipline and execution our teams are bringing to every part of our business," language that reads, in context, like a company still working its way back from a rough stretch rather than one declaring victory. A beat against a weak comparison, not against growth. Here is the number that deserves more attention than it is likely to get: Q3 2026 revenue of $112.7 billion was essentially flat against the $113.161 billion UnitedHealth booked in the same quarter a year earlier, per its year-ago quarterly filing. Top-line growth, in other words, has gone quiet. What moved was profitability - diluted earnings per share of $4.56 this time around dwarfs the $2.59 UnitedHealth managed in the third quarter of 2025, when a medical-cost blowup gutted margins across the group. That 2025 quarter was itself a recovery attempt from an even uglier stretch: UnitedHealth posted a net loss of $1.4 billion, or $1.53 a share, in the first quarter of 2024, before swinging back to multibillion-dollar profits through the rest of that year and into 2025. Set against that backdrop, this quarter's beat looks less like fresh momentum and more like a company normalising off a genuinely depressed base. Gurufocus, which covered the release alongside UnitedHealth's own filing, reported shares rising in premarket trading on the combination of the beat and the guidance raise, with other outlets putting the premarket pop at four to five%. By the time regular trading was under way, the move had settled to the 3.76% one-day gain reflected in consolidated exchange data - still a solid reaction, just not quite the premarket spike implied. Guidance keeps climbing off a low base. UnitedHealth had already nudged its full-year 2026 outlook to a range of $18.45 to $18.95 per share when it reported the second quarter, according to that earlier filing. Tuesday's raise builds on that base again, continuing a pattern of the company walking its numbers up gradually through the year rather than resetting expectations in one move - consistent with management steering through the aftermath of 2025's cost overruns rather than guiding into a period of expansion. CNBC separately confirmed the beat-and-raise framing, and transcript coverage of the earnings call points to management leaning heavily on cost discipline as the explanation, rather than enrolment or pricing gains. Quarterly profit has been genuinely choppy across the past two years: from the first-quarter 2024 loss, UnitedHealth swung to $4.2 billion in net income the following quarter, $6.1 billion in the third quarter of 2024, then $6.3 billion and $3.4 billion in the first two quarters of 2025 before the cost pressures hit hardest in the third quarter of that year. The $6.3 billion and $5.5 billion posted in the first two quarters of 2026 suggested the repair job was already under way before this latest print. Positioning data points to earnings-driven buying. Short-sale activity in UnitedHealth shares gives little indication that Tuesday's rally was a short squeeze - a rush of bearish traders buying back borrowed shares to close out losing bets. FINRA's daily short-sale ratio for the stock ranged roughly between 0.32 and 0.56 across the fortnight running into the results, with no sustained build-up or sudden unwind visible ahead of the print. That pattern points to the move being driven by the numbers themselves rather than positioning mechanics. The broader rates backdrop was quiet too: the 10-year Treasury yield sat at 5.22% on 8 October, down slightly from 5.28% days earlier, while the unemployment rate ticked up to 4.2% in September - neither shift large enough to explain a stock-specific move of this size. The quarter leaves UnitedHealth in a familiar position: profitable again, guiding higher again, but still searching for the top-line growth that once defined the stock's premium rating. Investors cheering the print on 13 October were, in effect, cheering a return to form rather than a new chapter - and the next test will be whether revenue growth reappears once the easy comparisons against 2025's cost crisis run out. This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.